Videos

Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber share their experiences in the use of intravesical botulinum toxin type A as a treatment option for overactive bladder (OAB) into treatment plans. They provide insight into identifying optimal candidates, the outcomes they have observed, and benefits and risks, including strategies for managing these risks. They explore the decision-making process in guiding patients through various treatment options, considering individual lifestyles and preferences.

Drs Helfand, Chapin, and Collins, review the case of 67-year-old man treated with recurring prostate cancer.

Clinical oncologists present the case of a 62-year-old man with recurrent prostate cancer.

“One of those gigs was the New York section of the AUA, we did a fundraising event, which was a battle of the bands with 2 other urology departments that had bands as well,” says Debra Fromer, MD.

"I don't think 1 database study creates dogma, but I do think we can share these data with our patients and talk to them about treatment options and risk, have that difficult conversation about how BMI may be associated with that risk," says Cassandra K. Kisby, MD, MS.

"If payments are cut, our overall cost per visit goes up, which could be another disincentive to use virtual care," says Chad Ellimoottil, MD, MS.

“Our conclusion was that the amount of pattern 3 in men with grade groups 2, 3, and 4 is not predictive of oncologic outcome once you know the amount of 4,” says Andrew J. Vickers, PhD.

"What we found was that we were able to identify patients who responded vs didn't respond to the treatment with a high degree of accuracy," says Glenn T. Werneburg, MD, PhD.

"We're going to look at whether that difference in the protocol has clinically meaningful implications, such as are patients who receive antibiotic prophylaxis at higher risk of developing resistance in the future?" says Badar M. Mian, MD.

"I emphasized the fact that the use of ultrasound is very important and should be done on every single case," says Nazih Paul Khater, MD, FACS.

“But all in all, one thing we did see was that [with] the data for saw palmetto, there was a signal that does seem promising, especially when used in combination with other agents,” says Bilal Chughtai, MD.

"The biggest finding was that the guys lost the weight. They lost 5.5% of their body weight," says Jill M. Hamilton Reeves, PhD, RD, CSO.

"The most important thing that I think came out of this study is really the BMI inflection point for complications. We saw an abrupt rise in complications around a BMI of 40," says Cassandra K. Kisby, MD, MS.

“We don't have the sex therapists or psychologists who specialize in sexual dysfunction here... It's incredibly important, because if it doesn't start out as psychological, certainly, it becomes psychological, at least in some measure,” says Thomas M. Jaffe, MD.

Experts in prostate cancer evaluate the data from the SPOTLIGHT trial and the use of 18F-rhPSMA-7.3 for prostate cancer.

A panel of experts introduce the SPOTLIGHT study, evaluating PSMA PET in patients with prostate cancer.

"I would say that the biggest take-home is that many of our patients are using social media for their health care information, and this may influence their preferences [and] their decision-making," says Alexandra Tabakin, MD.

"The learning curve is fairly quick; you can pick this up pretty easily vs some of the other prostate procedures that can take a little bit more time to learn how to use," says Matthew E. Sterling, MD.

In this episode, Dr. Kennelly, alongside Dr. Eilber and Dr. Benson, explores the advancements of transcutaneous and posterior tibial nerve stimulation (TTNS and PTNS) and sacral neuromodulation (SNM). The episode sheds light on how these therapies fit into current medical practices, their effectiveness, and the convenience they offer to patients. The specialists consider patient preferences and compliance challenges in choosing the right therapy. The episode provides a comprehensive understanding of how these therapies fit into patient-centric management plans, offering valuable insights for both patients and healthcare professionals.

In this insightful episode, Dr. Kennelly, along with Dr. Eilber and Dr. Benson, discuss the transition from pharmacologic treatments to third-line therapies for overactive bladder, focusing on the mechanism of action of various neuromodulation methods and benefits they offer to patients seeking sustainable solutions for OAB management.

"in general, we can use a simpler regimen [of testosterone replacement therapy] and achieve normal levels," says Peter N. Tsambarlis, MD.

“What we found was that the rate of complications due to infection were 2.6% with the transrectal approach, and 2.7% with the transperineal,” says Badar M. Mian, MD.

"There are situations where you can use a biparametric or noncontrast approach; most of them you will prefer still to use an approach with contrast," says Leonardo Kayat Bittencourt, MD, PhD.

“With 2 years of follow-up, we saw that there was no difference in these 2 groups in terms of overall survival, metastasis-free survival, or recurrence-free survival,” says Saum B. Ghodoussipour, MD.

"You could look at a person and say that they're extraordinarily successful...but they can be completely miserable," says Anne M. Suskind, MD, MS, FACS, FPMRS.

"Probably the most surprising finding was actually that there were several videos created by health care professionals that contain misinformation," says Alexandra Tabakin, MD.

“We’re in a very exciting time for those of us who take care of patients with bladder cancer. There are a lot of new emerging treatment options,” says Vikram M. Narayan, MD.

“In this study, we sought to compare our early outcomes with transperineal prostate biopsy compared to transrectal,” says Saum B. Ghodoussipour, MD.

"We had interest in trying to look at mechanisms and seeing if the obvious question is, well, if obesity is associated with progressing cancer, can we disrupt that link if we help men lose weight in a healthy way," says Jill Hamilton Reeves, PhD, RD, CSO.